Edison
Edison TV
Executive interview – Silence Therapeutics

Executive interview – Silence Therapeutics

Register to receive research on Silence Therapeutics as it is published

Published on 18 July 2019

In this interview with David Horn Solomon, CEO of Silence Therapeutics, he discusses today’s announcement of a licensing and collaboration agreement with Mallinckrodt Pharmaceuticals to develop and commercialise RNAi drugs.

Executive interview – Silence Therapeutics

You may also be interested in these

Top five themes from Edison Open House you need to watch

Healthcare

Aspire Global – executive interview

Consumer

Axiom European Financial Debt Fund – executive interview

Investment companies

VivoPower helps football go carbon neutral

Industrials